Edwin Rock - 21 Sep 2023 Form 4 Insider Report for GLYCOMIMETICS INC (GLYC)

Role
Chief Medical Officer
Signature
/s/ Brian F. Leaf, attorney-in-fact
Issuer symbol
GLYC
Transactions as of
21 Sep 2023
Net transactions value
+$90,256
Form type
4
Filing time
25 Sep 2023, 16:21:40 UTC
Previous filing
20 Jan 2023
Next filing
17 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GLYC Common Stock Purchase $48,300 +35,000 +11% $1.38 345,000 21 Sep 2023 Direct F1
transaction GLYC Common Stock Purchase $41,956 +30,403 +8.8% $1.38 375,403 22 Sep 2023 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person purchased the securities on the open market at purchase prices ranging from $1.35 to $1.40 per share, with a weighted average purchase price of $1.38 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
F2 The Reporting Person purchased the securities on the open market at purchase prices ranging from $1.37 to $1.40 per share, with a weighted average purchase price of $1.38 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.